BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Heida A, Park KT, van Rheenen PF. Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide. Inflamm Bowel Dis. 2017;23:894-902. [PMID: 28511198 DOI: 10.1097/mib.0000000000001082] [Cited by in Crossref: 64] [Cited by in F6Publishing: 19] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Tandon P, Lee EY, Maxwell C, Hitz L, Ambrosio L, Dieleman L, Halloran B, Kroeker K, Huang VM. Fecal Calprotectin May Predict Adverse Pregnancy-Related Outcomes in Patients with Inflammatory Bowel Disease. Dig Dis Sci 2021;66:1639-49. [PMID: 32533542 DOI: 10.1007/s10620-020-06381-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Teng X, Gao C, Sun M, Wu J. Clinical significance of fecal calprotectin for the early diagnosis of abdominal type of Henoch-Schonlein purpura in children. Clin Rheumatol 2018;37:1667-73. [PMID: 29018973 DOI: 10.1007/s10067-017-3864-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
3 Røer MJ, Småstuen MC, Røseth AG. Usability of IBDoc, a Novel Fecal Calprotectin Home-Based Rapid Test in Clinical Practice. Point of Care 2019;18:85-91. [DOI: 10.1097/poc.0000000000000192] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Guerra ENS, Acevedo AC, de Toledo IP, Combes A, Chardin H. Do mucosal biomarkers reveal the immunological state associated with food allergy? Allergy 2018;73:2392-4. [PMID: 30035802 DOI: 10.1111/all.13571] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
5 Bathe AL, Mavropoulou E, Mechie NC, Petzold G, Ellenrieder V, Kunsch S, Amanzada A. Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn's disease and ulcerative colitis. PLoS One 2019;14:e0223893. [PMID: 31647834 DOI: 10.1371/journal.pone.0223893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Vaughan R, Tjandra D, Patwardhan A, Mingos N, Gibson R, Boussioutas A, Ardalan Z, Al-Ani A, Gibson PR, Christensen B. Toward transmural healing: Sonographic healing is associated with improved long-term outcomes in patients with Crohn's disease. Aliment Pharmacol Ther 2022;56:84-94. [PMID: 35343603 DOI: 10.1111/apt.16892] [Reference Citation Analysis]
7 Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients' and physicians' preferences and adherence. Scand J Gastroenterol 2021;:1-8. [PMID: 34779308 DOI: 10.1080/00365521.2021.2002397] [Reference Citation Analysis]
8 Velasco Rodríguez-Belvís M, Viada Bris JF, Plata Fernández C, García-Salido A, Asensio Antón J, Domínguez Ortega G, Muñoz Codoceo RA. Normal fecal calprotectin levels in healthy children are higher than in adults and decrease with age. Paediatr Child Health 2020;25:286-92. [PMID: 32765164 DOI: 10.1093/pch/pxz070] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lężyk-Ciemniak E, Tworkiewicz M, Wilczyńska D, Szaflarska-Popławska A, Krogulska A. Usefulness of Testing for Fecal Calprotectin in Pediatric Gastroenterology Clinical Practice. Med Princ Pract 2021;30:311-9. [PMID: 33120396 DOI: 10.1159/000512631] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignass A, Kucharzik T; Collaborators:. Addendum to S3-Guidelines Crohn’s disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic – open questions and answers. Z Gastroenterol 2020;58:982-1002. [DOI: 10.1055/a-1234-8079] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
11 Stallmach A, Sturm A, Blumenstein I, Helwig U, Koletzko S, Lynen P, Schmidt C, Dignaß A, Kucharzik T; Collaborators:. [Addendum to S3-Guidelines Crohn's disease and ulcerative colitis: Management of Patients with Inflammatory Bowel Disease in the COVID-19 Pandemic - open questions and answers]. Z Gastroenterol 2020;58:672-92. [PMID: 32659830 DOI: 10.1055/a-1193-5475] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
12 Nilsen T, Haugen SH, Larsson A. Extraction, isolation, and concentration of calprotectin antigen (S100A8/S100A9) from granulocytes. Health Sci Rep 2018;1:e35. [PMID: 30623070 DOI: 10.1002/hsr2.35] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
13 Soomro S, Venkateswaran S, Vanarsa K, Kharboutli M, Nidhi M, Susarla R, Zhang T, Sasidharan P, Lee KH, Rosh J, Markowitz J, Pedroza C, Denson LA, Hyams J, Kugathasan S, Mohan C. Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen. Nat Commun 2021;12:3989. [PMID: 34183667 DOI: 10.1038/s41467-021-24235-0] [Reference Citation Analysis]
14 Turner D, Griffiths AM, Wilson D, Mould DR, Baldassano RN, Russell RK, Dubinsky M, Heyman MB, de Ridder L, Hyams J, Martin de Carpi J, Conklin L, Faubion WA, Koletzko S, Bousvaros A, Ruemmele FM. Designing clinical trials in paediatric inflammatory bowel diseases: a PIBDnet commentary. Gut 2020;69:32-41. [PMID: 30979718 DOI: 10.1136/gutjnl-2018-317987] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 8.5] [Reference Citation Analysis]
15 Sathananthan D, Rajagopalan A, Van De Ven L, Martin S, Fon J, Costello S, Bryant RV. Point-of-care gastrointestinal ultrasound in inflammatory bowel disease: An accurate alternative for disease monitoring. JGH Open 2020;4:273-9. [PMID: 32280777 DOI: 10.1002/jgh3.12269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
16 Borg-Bartolo SP, Boyapati RK, Satsangi J, Kalla R. Precision medicine in inflammatory bowel disease: concept, progress and challenges. F1000Res. 2020;9. [PMID: 32047622 DOI: 10.12688/f1000research.20928.1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
17 van den Brink G, Stapersma L, Bom AS, Rizopolous D, van der Woude CJ, Stuyt RJL, Hendriks DM, van der Burg JAT, Beukers R, Korpershoek TA, Theuns-Valks SDM, Utens EMWJ, Escher JC. Effect of Cognitive Behavioral Therapy on Clinical Disease Course in Adolescents and Young Adults With Inflammatory Bowel Disease and Subclinical Anxiety and/or Depression: Results of a Randomized Trial. Inflamm Bowel Dis 2019;25:1945-56. [PMID: 31050763 DOI: 10.1093/ibd/izz073] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 Bouhuys M, Lexmond WS, Dijkstra G, Lobatón T, Louis E, van Biervliet S, Groen H, Guardiola J, Rheenen PV. Efficacy of anti-TNF dosing interval lengthening in adolescents and young adults with inflammatory bowel disease in sustained remission (FREE-study): protocol for a partially randomised patient preference trial. BMJ Open 2021;11:e054154. [PMID: 34732500 DOI: 10.1136/bmjopen-2021-054154] [Reference Citation Analysis]
19 Fernandes SR, Rodrigues IC, Serrazina J, Botto IA, Bernardo S, Gonçalves AR, Valente A, Moura Santos P, Correia LA, Marinho RT. Proactive infliximab is more effective than vedolizumab in inducing fecal calprotectin remission in inflammatory bowel disease. Scandinavian Journal of Gastroenterology. [DOI: 10.1080/00365521.2022.2076567] [Reference Citation Analysis]
20 Dijkstra A, Heida A, van Rheenen PF. Exploring the Challenges of Implementing a Web-Based Telemonitoring Strategy for Teenagers With Inflammatory Bowel Disease: Empirical Case Study. J Med Internet Res 2019;21:e11761. [PMID: 30924785 DOI: 10.2196/11761] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
21 Gonczi L, Bessissow T, Lakatos PL. Disease monitoring strategies in inflammatory bowel diseases: What do we mean by “tight control”? World J Gastroenterol 2019; 25(41): 6172-6189 [PMID: 31749591 DOI: 10.3748/wjg.v25.i41.6172] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
22 Foster AJ, Smyth M, Lakhani A, Jung B, Brant RF, Jacobson K. Consecutive fecal calprotectin measurements for predicting relapse in pediatric Crohn’s disease patients. World J Gastroenterol 2019; 25(10): 1266-1277 [PMID: 30886509 DOI: 10.3748/wjg.v25.i10.1266] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
23 Wilkens R, Dolinger M, Burisch J, Maaser C. Point-of-Care Testing and Home Testing: Pragmatic Considerations for Widespread Incorporation of Stool Tests, Serum Tests, and Intestinal Ultrasound. Gastroenterology 2022:S0016-5085(21)04072-5. [PMID: 34995530 DOI: 10.1053/j.gastro.2021.10.052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
24 Borren NZ, Plichta D, Joshi AD, Bonilla G, Sadreyev R, Vlamakis H, Xavier RJ, Ananthakrishnan AN. Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflamm Bowel Dis 2020;26:1524-32. [PMID: 32766830 DOI: 10.1093/ibd/izaa183] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
25 Mumolo MG, Bertani L, Ceccarelli L, Laino G, Di Fluri G, Albano E, Tapete G, Costa F. From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting. World J Gastroenterol 2018; 24(33): 3681-3694 [PMID: 30197475 DOI: 10.3748/wjg.v24.i33.3681] [Cited by in CrossRef: 71] [Cited by in F6Publishing: 54] [Article Influence: 17.8] [Reference Citation Analysis]
26 Albenberg L, Brensinger CM, Wu Q, Gilroy E, Kappelman MD, Sandler RS, Lewis JD. A Diet Low in Red and Processed Meat Does Not Reduce Rate of Crohn's Disease Flares. Gastroenterology 2019;157:128-136.e5. [PMID: 30872105 DOI: 10.1053/j.gastro.2019.03.015] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 13.3] [Reference Citation Analysis]
27 Iwańczak B, Ruczka M, Matusiewicz M, Pytrus T, Matusiewicz K, Krzesiek E. Correlation between biomarkers (calprotectin, seromucoid, metalloproteinase-3 and CRP) and clinical and endoscopic activity of ulcerative colitis in children. Adv Med Sci 2020;65:259-64. [PMID: 32361483 DOI: 10.1016/j.advms.2020.03.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
28 Colombel JF, Shin A, Gibson PR. AGA Clinical Practice Update on Functional Gastrointestinal Symptoms in Patients With Inflammatory Bowel Disease: Expert Review. Clin Gastroenterol Hepatol. 2019;17:380-390.e1. [PMID: 30099108 DOI: 10.1016/j.cgh.2018.08.001] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 10.5] [Reference Citation Analysis]
29 Haisma SM, Galaurchi A, Almahwzi S, Adekanmi Balogun JA, Muller Kobold AC, van Rheenen PF. Head-to-head comparison of three stool calprotectin tests for home use. PLoS One 2019;14:e0214751. [PMID: 30998692 DOI: 10.1371/journal.pone.0214751] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
30 Wagatsuma K, Yokoyama Y, Nakase H. Role of Biomarkers in the Diagnosis and Treatment of Inflammatory Bowel Disease. Life (Basel) 2021;11:1375. [PMID: 34947906 DOI: 10.3390/life11121375] [Reference Citation Analysis]
31 Barfield E, Sockolow R, Hoffenberg E, Saeed S, Kim S, Siebold L, Picoraro J, Moses J, Dykes D, Grossman A, Wahbeh G, Park KT. Assuring Quality for Non-hospital-based Biologic Infusions in Pediatric Inflammatory Bowel Disease: A Clinical Report From the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 2018;66:680-6. [PMID: 29324477 DOI: 10.1097/MPG.0000000000001890] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
32 Roca M, Rodriguez Varela A, Carvajal E, Donat E, Cano F, Armisen A, Vaya MJ, Ekoff H, Hervas D, Rydell N, Ribes-Koninckx C. Fecal calprotectin in healthy children aged 4-16 years. Sci Rep 2020;10:20565. [PMID: 33239728 DOI: 10.1038/s41598-020-77625-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
33 Af Björkesten CG, Jussila A, Kemppainen H, Hallinen T, Soini E, Mankinen P, Valgarðsson S, Veckman V, Nissinen R, Naessens D, Molander P. Relationship of faecal calprotectin and long-term outcomes in Finnish patients with Crohn's disease: retrospective multi-centre chart review study. Scand J Gastroenterol 2019;54:1226-32. [PMID: 31532265 DOI: 10.1080/00365521.2019.1667426] [Reference Citation Analysis]
34 Wetwittayakhlang P, Lontai L, Gonczi L, Golovics PA, Hahn GD, Bessissow T, Lakatos PL. Treatment Targets in Ulcerative Colitis: Is It Time for All In, including Histology? J Clin Med 2021;10:5551. [PMID: 34884252 DOI: 10.3390/jcm10235551] [Reference Citation Analysis]
35 Sturm A, Atreya R, Bettenworth D, Bokemeyer B, Dignaß A, Ehehalt R, Germer C, Grunert PC, Helwig U, Herrlinger K, Kienle P, Kreis ME, Kucharzik T, Langhorst J, Maaser C, Ockenga J, Ott C, Siegmund B, Zeißig S, Stallmach A; Collaborators:. Aktualisierte S3-Leitlinie „Diagnostik und Therapie des Morbus Crohn“ der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – August 2021 – AWMF-Registernummer: 021-004. Z Gastroenterol 2022;60:332-418. [PMID: 35263784 DOI: 10.1055/a-1713-3941] [Reference Citation Analysis]
36 Chen ZR, Liu G. Fecal calprotectin and colorectal cancer. Shijie Huaren Xiaohua Zazhi 2019; 27(23): 1436-1440 [DOI: 10.11569/wcjd.v27.i23.1436] [Reference Citation Analysis]